Pet Cancer Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 – 2034
The Global Pet Cancer Therapeutics Market reached USD 477.1 million in 2024 and is anticipated to grow at a CAGR of 9.7% from 2025 to 2034. This growth is primarily attributed to the rising trend of pet humanization, as pet owners increasingly prioritize advanced healthcare for their animals. Enhanced diagnostic capabilities and cutting-edge treatments, including targeted therapies and immunotherapies, are further boosting the accessibility and effectiveness of veterinary cancer care.
The aging pet population has led to a higher prevalence of cancer, significantly driving the demand for oncology solutions. This evolution in consumer behavior, combined with continual advancements in veterinary medicine, underlines the growing market need for innovative and life-prolonging treatments for pets.
The market is segmented by species into dogs, cats, and other animals. Dogs held the largest market share, valued at USD 402 million in 2024. This dominance is attributed to the higher incidence of cancers such as lymphoma, osteosarcoma, and mammary tumors in dogs compared to other pets. The growing need for specialized treatments in canine oncology continues to propel the demand for effective therapeutic options.
By therapy, the market includes chemotherapy, immunotherapy, targeted therapy, and combination therapy. Chemotherapy emerged as the leading segment, generating a 62.1% share in 2024. Known for its efficacy in targeting and inhibiting the growth of cancer cells, chemotherapy remains a cornerstone of treatment for various cancers, particularly lymphoma and mast cell tumors. Its high success rates in remission, especially for common canine cancers, ensure its continued prominence in veterinary oncology.
U.S. pet cancer therapeutics market held a CAGR of 9.3% throughout 2025-2034. This leadership is driven by the country’s robust veterinary healthcare infrastructure, high pet ownership rates, and widespread awareness of advanced cancer treatments. Significant investments in veterinary oncology research and technology enable the development of innovative therapies, including immunotherapy and targeted treatments, further strengthening the U.S. market.
Additionally, the increasing prevalence of cancer among aging pets continues to fuel the demand for high-quality therapeutic solutions. As awareness and adoption of advanced veterinary care rise, the pet cancer therapeutics market is expected to witness robust growth globally, with North America maintaining a pivotal role in shaping industry trends.
The aging pet population has led to a higher prevalence of cancer, significantly driving the demand for oncology solutions. This evolution in consumer behavior, combined with continual advancements in veterinary medicine, underlines the growing market need for innovative and life-prolonging treatments for pets.
The market is segmented by species into dogs, cats, and other animals. Dogs held the largest market share, valued at USD 402 million in 2024. This dominance is attributed to the higher incidence of cancers such as lymphoma, osteosarcoma, and mammary tumors in dogs compared to other pets. The growing need for specialized treatments in canine oncology continues to propel the demand for effective therapeutic options.
By therapy, the market includes chemotherapy, immunotherapy, targeted therapy, and combination therapy. Chemotherapy emerged as the leading segment, generating a 62.1% share in 2024. Known for its efficacy in targeting and inhibiting the growth of cancer cells, chemotherapy remains a cornerstone of treatment for various cancers, particularly lymphoma and mast cell tumors. Its high success rates in remission, especially for common canine cancers, ensure its continued prominence in veterinary oncology.
U.S. pet cancer therapeutics market held a CAGR of 9.3% throughout 2025-2034. This leadership is driven by the country’s robust veterinary healthcare infrastructure, high pet ownership rates, and widespread awareness of advanced cancer treatments. Significant investments in veterinary oncology research and technology enable the development of innovative therapies, including immunotherapy and targeted treatments, further strengthening the U.S. market.
Additionally, the increasing prevalence of cancer among aging pets continues to fuel the demand for high-quality therapeutic solutions. As awareness and adoption of advanced veterinary care rise, the pet cancer therapeutics market is expected to witness robust growth globally, with North America maintaining a pivotal role in shaping industry trends.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increased pet humanization
3.2.1.2 Rising cancer incidence in pets
3.2.1.3 Advancements in veterinary oncology diagnosis and treatment
3.2.1.4 Growing awareness and diagnostic capabilities
3.2.2 Industry pitfalls and challenges
3.2.2.1 High treatment costs
3.2.2.2 Side effects and animal tolerance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY SPECIES, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Dogs
5.3 Cats
5.4 Other species
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY THERAPY, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Chemotherapy
6.3 Immunotherapy
6.4 Targeted therapy
6.5 Combination therapy
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 Oral
7.3 Injection
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY CANCER TYPE, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 Lymphoma
8.3 Mast cell cancer
8.4 Melanoma
8.5 Mammary and squamous cell cancer
8.6 Other cancer types
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
CHAPTER 10 COMPANY PROFILES
10.1 AB Science
10.2 Boehringer Ingelheim International
10.3 CureLab Oncology
10.4 Dechra Pharmaceuticals
10.5 Elanco Animal Health
10.6 ELIAS Animal Health
10.7 NovaVive
10.8 Qbiotics
10.9 Pfizer
10.10 Torigen
10.11 Vibrac
10.12 Vivesto
10.13 Zoetis
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increased pet humanization
3.2.1.2 Rising cancer incidence in pets
3.2.1.3 Advancements in veterinary oncology diagnosis and treatment
3.2.1.4 Growing awareness and diagnostic capabilities
3.2.2 Industry pitfalls and challenges
3.2.2.1 High treatment costs
3.2.2.2 Side effects and animal tolerance
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY SPECIES, 2021 – 2034 ($ MN)
5.1 Key trends
5.2 Dogs
5.3 Cats
5.4 Other species
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY THERAPY, 2021 – 2034 ($ MN)
6.1 Key trends
6.2 Chemotherapy
6.3 Immunotherapy
6.4 Targeted therapy
6.5 Combination therapy
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY ROUTE OF ADMINISTRATION, 2021 – 2034 ($ MN)
7.1 Key trends
7.2 Oral
7.3 Injection
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY CANCER TYPE, 2021 – 2034 ($ MN)
8.1 Key trends
8.2 Lymphoma
8.3 Mast cell cancer
8.4 Melanoma
8.5 Mammary and squamous cell cancer
8.6 Other cancer types
CHAPTER 9 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 ($ MN)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
CHAPTER 10 COMPANY PROFILES
10.1 AB Science
10.2 Boehringer Ingelheim International
10.3 CureLab Oncology
10.4 Dechra Pharmaceuticals
10.5 Elanco Animal Health
10.6 ELIAS Animal Health
10.7 NovaVive
10.8 Qbiotics
10.9 Pfizer
10.10 Torigen
10.11 Vibrac
10.12 Vivesto
10.13 Zoetis
